Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue		$ 979	$ 166	$ 1,989	$ 612
Operating expenses:
Cost of revenue		1,666	1,685	3,411	3,030
Sales and marketing		4,242	4,339	8,552	8,877
General and administrative		7,009	6,652	13,688	17,060
Amortization of acquired intangible assets		105	505	477	1,010
Research and development		1,641	3,469	3,583	7,519
Total operating expenses		14,663	16,650	29,711	37,496
Operating loss		(13,684)	(16,484)	(27,722)	(36,884)
Other income (expense):
Interest income		110	163	182	283
Interest expense		(11)	(228)	(26)	(411)
Change in fair value - Senior Secured Convertible Notes		(566)	(340)	(2,728)	(1,380)
Loss on issue and offering costs - Senior Secured Convertible Note					(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes		(763)	(743)	(1,132)	(1,268)
Debt modification expense				(2,000)
Change in fair value - derivative liability			(260)		(260)
Gain on sale of intellectual property					1,000
Other income (expense), net		(1,230)	(1,408)	(5,704)	(3,222)
Loss before provision for income tax		(14,914)	(17,892)	(33,426)	(40,106)
Provision for income taxes
Net loss before noncontrolling interests		(14,914)	(17,892)	(33,426)	(40,106)
Net loss attributable to the noncontrolling interests		4,087	3,355	7,387	7,638
Net loss attributable to PAVmed Inc.		(10,827)	(14,537)	(26,039)	(32,468)
Less: Series B Convertible Preferred Stock dividends earned		(81)	(75)	(161)	(149)
Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (10,908)	$ (14,612)	$ (33,696)	$ (32,617)
Per share information:
Net loss per share attributable to PAVmed Inc. common stockholders - diluted	[1]	$ (1.19)	$ (2.10)	$ (3.78)	$ (4.86)
Net loss per share attributable to PAVmed Inc. common stockholders - basic	[1]		$ (2.10)		$ (4.86)
Weighted average common shares outstanding, basic		9,152,819	6,956,655	8,923,862	6,716,169
Weighted average common shares outstanding, diluted		9,152,819	6,956,655	8,923,862	6,716,169

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.